Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$774M |
| 2 |
Intuitive Surgical
ISRG
|
+$654M |
| 3 |
S&P Global
SPGI
|
+$464M |
| 4 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$326M |
| 5 |
CELG
Celgene Corp
CELG
|
+$243M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
FedEx
FDX
|
+$591M |
| 2 |
Broadcom
AVGO
|
+$550M |
| 3 |
Monster Beverage
MNST
|
+$408M |
| 4 |
Booking.com
BKNG
|
+$377M |
| 5 |
McDonald's
MCD
|
+$371M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 22.27% |
| 2 | Consumer Discretionary | 16.23% |
| 3 | Healthcare | 15.49% |
| 4 | Financials | 12.97% |
| 5 | Communication Services | 11.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
426
KLX Energy Services
KLXE
$44.4M
| $15.9M | 0.01% |
+99,593
| New | +$15M |
|
|
NUVA
427
DELISTED
NuVasive, Inc.
NUVA
| $15.8M | 0.01% |
223,239
+4
| +0% | +$255 |
|
428
Nutrien
NTR
$33.9B
| $15.5M | 0.01% |
268,071
+31,991
| +14% | +$1.77M |
|
429
ProPetro Holding
PUMP
$1.33B
| $15.4M | 0.01% |
934,913
-1,381,033
| -60% | -$22.3M |
|
|
ALLK
430
DELISTED
Allakos
ALLK
| $15.4M | 0.01% |
+341,802
| New | +$14M |
|
|
EIGR
431
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
| $15.2M | 0.01% |
42,133
+250
| +0.6% | +$85.5K |
|
432
Agios Pharmaceuticals
AGIO
$1.95B
| $15.1M | 0.01% |
195,370
+1,435
| +0.7% | +$115K |
|
|
TSRO
433
DELISTED
TESARO, Inc.
TSRO
| $14.9M | 0.01% |
382,114
-3,634
| -0.9% | -$128K |
|
434
MPLX
MPLX
$58.5B
| $14.9M | 0.01% |
428,264
-660,227
| -61% | -$23.6M |
|
435
Freeport-McMoran
FCX
$91.2B
| $14.8M | 0.01% |
1,062,837
-55,205
| -5% | -$834K |
|
436
Spyre Therapeutics
SYRE
$8.81B
| $14.7M | 0.01% |
61,296
+278
| +0.5% | +$64.9K |
|
437
BrightView Holdings
BV
$1.23B
| $14.6M | 0.01% |
912,179
+21,491
| +2% | +$422K |
|
|
RDC
438
DELISTED
Rowan Companies Plc
RDC
| $14.3M | 0.01% |
757,793
+260,965
| +53% | +$3.91M |
|
|
CTLT
439
DELISTED
CATALENT, INC.
CTLT
| $14.1M | 0.01% |
+309,627
| New | +$13.1M |
|
440
Elanco Animal Health
ELAN
$13.2B
| $14M | 0.01% |
+400,000
| New | +$14.1M |
|
|
OLBK
441
DELISTED
Old Line Bancshares, Inc.
OLBK
| $13.7M | 0.01% |
434,273
+421,421
| +3,279% | +$14.4M |
|
|
SYNH
442
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
| $13.7M | 0.01% |
266,116
-64,090
| -19% | -$3.14M |
|
|
GSKY
443
DELISTED
GreenSky, Inc. Class A Common Stock
GSKY
| $13.5M | 0.01% |
751,710
-48,290
| -6% | -$921K |
|
|
EQM
444
DELISTED
EQM Midstream Partners, LP
EQM
| $13.4M | 0.01% |
253,824
+10,949
| +5% | +$597K |
|
|
PARA
445
DELISTED
Paramount Global Class B
PARA
| $13.4M | 0.01% |
+232,638
| New | +$12.8M |
|
446
Diamondback Energy
FANG
$56.2B
| $13M | 0.01% |
+96,201
| New | +$12.3M |
|
|
AM
447
DELISTED
ANTERO MIDSTREAM PARTNERS LP
AM
| $13M | 0.01% |
453,080
+18,544
| +4% | +$568K |
|
448
Kosmos Energy
KOS
$1.52B
| $12.8M | 0.01% |
1,367,583
+366,528
| +37% | +$3.1M |
|
449
Box
BOX
$4.31B
| $12.8M | 0.01% |
534,387
-2,243
| -0.4% | -$56.5K |
|
450
Constellium
CSTM
$3.87B
| $12.7M | 0.01% |
1,030,000
-265,508
| -20% | -$3.11M |
|
Similar funds
Jennison Associates's Q3 2018 Portfolio in Review
As of Q3 2018, Jennison Associates held 739 positions worth $109B, up 5.9% from $103B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Jennison Associates's Q3 2018 filing shows 86 new, 214 increased, 352 reduced and 81 closed positions. Its largest new stake was Tiffany & Co.: 1,169,094 shares worth $151M. The largest sale was FedEx, an estimated $591M.
By sector, the portfolio is most concentrated in Technology at 22% of assets, up from 21% a quarter earlier, followed by Consumer Discretionary and Healthcare.
- Jennison Associates's largest Q3 2018 buy was Tiffany & Co.: 1,169,094 shares worth $151M.
- Jennison Associates added most to AstraZeneca in Q3 2018, an estimated $774M increase.
- Jennison Associates's biggest Q3 2018 reduction was FedEx, cutting an estimated $591M.
- Jennison Associates fully exited Cheniere Energy Partners LP Holdings LLC in Q3 2018, selling an estimated $134M.
- Jennison Associates's ten largest holdings make up 30% of its $109B portfolio in Q3 2018.
- Jennison Associates opened 86 new positions and closed 81 in Q3 2018.
- Jennison Associates's portfolio value rose 5.9% quarter-over-quarter to $109B.
Based on Jennison Associates's 13F filing for Q3 2018, filed 8 Nov 2018.